Promising results with the daily oral small molecule lipoprotein(a) inhibitor, muvalaplin, in high-risk cardiovascular patients with elevated lipoprotein(a) levels.
作者信息
Vuorio Alpo, Kovanen Petri T, Raal Frederick
机构信息
Mehiläinen Airport Health Centre, Vantaa, Finland.
Department of Forensic Medicine, University of Helsinki, Helsinki, Finland.
出版信息
Ann Transl Med. 2025 Apr 30;13(2):11. doi: 10.21037/atm-25-40. Epub 2025 Apr 29.
Abstract
摘要
Zotero 插件